A Randomized, Double-blind,Dose-escalating, Single-dose, Oral Phase I Clinical Study of Flunotinib Healthy People

A Randomized, Double-blind, Placebo-controlled, Dose-escalating, Single-dose, Oral Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of Flunotinib Maleate Tablets in Healthy Adult Subjects in China.

Evaluate the safety and tolerability of a single increasing dose of Flibanserin Maleate tablets administered orally to healthy adult Chinese subjects; preliminarily assess the pharmacokinetic characteristics of a single dose of oral Flibanserin Maleate tablets

Study Overview

• Status: Recruiting
• Conditions: Healthy Person
• Intervention / Treatment: Drug: flunotinib; Drug: flunotinib placebo

Detailed Description

The goal of this clinical trial is to evaluate the safety of sflunotinib maleate tablets. The main question[s] it aims to answer are:

1. The safety and tolerability of single oral doses of flunotinib maleate tablets in escalating doses in healthy adult subjects in China
2. The pharmacokinetic characteristics of a single dose of oral flunotinib maleate tablets Participants will divide into experimental group and placebo group, conduct single oral administration safety and tolerability test group by group

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Liangkun Sun, bachelor; Phone Number: 15885742617; Email: liangkunsun@zenitar.cn

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China, 610000
      • Recruiting
      • Chengdu Xinhua Hospital
      • Contact: Xiaolan Yong, bachelor; Phone Number: 13568843829; Email: yongxlan@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Age and gender: 18 to 45 years old (including 18 and 45 years old), no gender limit;
2. The weight of male subjects is ≥50.0 kg, the weight of female subjects is ≥45.0 kg, and the body mass index (BMI) is between 19.0 and 25.0 kg/m2 (including the boundary value);
3. Those who fully understand the trial content, trial drugs, trial process, etc., can communicate well with the researchers, are willing to comply with the research regulations, voluntarily participate in the trial and sign the informed consent form.

Exclusion Criteria:

1. (Screening period consultation/check-in consultation) Those with a history of severe allergies (such as angioedema and anaphylactic shock), allergies (such as allergies to pollen, two or more drugs/foods), or those with Those who are judged by the researcher to have a clinically significant history of food or drug allergies or other allergic diseases (asthma, urticaria, eczematous dermatitis, etc.); or those who are known to be allergic to JAK inhibitors or to excipients contained in the trial drug ;
2. Pre-selection physical examination, vital signs, 12-lead electrocardiogram, laboratory tests (including: blood routine, blood biochemistry, urine routine, blood pregnancy (females only), infectious disease screening, antinuclear antibodies, coagulation function , tuberculosis antibodies, chest anteroposterior X-ray examination, abdominal color ultrasound) results are abnormal and clinically significant;
3. During the screening period, the electrocardiogram showed QTcF > 440 ms for men and QTcF > 460 ms for women;
4. (Screening period consultation/check-in consultation) Those who have undergone major surgical operations within 3 months before screening or plan to undergo surgery during the trial;
5. (Screening period consultation) Those who suffer from acute diseases within 2 weeks before screening; those who have clinically significant infections (such as upper respiratory tract infection, nasopharyngitis, urinary system infection, etc.) within 3 months before screening; those who have any symptoms within 7 days before screening Those with evidence of infection; those with a history of herpes simplex infection or recurrent (>1) herpes zoster or disseminated herpes zoster.
6. (Screening period consultation/check-in consultation) Have any history of serious clinical diseases or diseases or conditions that the researcher believes may affect the test results, including but not limited to the circulatory system, endocrine system, nervous system, digestive system, urinary system or History of blood, immune, psychiatric and metabolic diseases;
7. (Inquiry during the screening period) Those with a history of dysphagia or any gastrointestinal system disease (or gastrointestinal resection, etc.) that affects drug absorption;
8. (Inquiry during the screening period) Those with irregular bowel movements and habitual constipation or diarrhea;
9. (Inquiry during the screening period) Those with a history of lipid metabolism defects, such as: familial hyperlipidemia, lipoid nephropathy, or patients with acute pancreatitis accompanied by hyperlipidemia, etc.;
10. Those whose urine is positive for multiple combined drug tests (including morphine, methamphetamine, ketamine, methylenedioxyamphetamine, and tetrahydrocannabinolic acid);
11. (Screening period consultation/check-in consultation) Those who have a history of drug abuse or drug dependence;
12. (Screening period consultation/check-in consultation) Those who have been vaccinated within 8 weeks before screening, or plan to be vaccinated during the study or within 8 weeks after the administration of study drugs;
13. (Screening period consultation/check-in consultation) Those who have donated blood or lost ≥400 mL of blood or received blood transfusions within 3 months before screening; or those who have donated blood or blood components within 1 month after the planned trial ends;
14. (Screening period consultation) Those who have special requirements for diet or cannot comply with the unified diet and corresponding regulations of the research center;
15. (Screening period consultation/check-in consultation) Those who smoke more than 3 cigarettes/day or the same amount of tobacco within 3 months before screening; or drink ≥14 units of alcohol per week (1 unit is equal to 17.5mL or 14g of pure alcohol, Approximately equal to 35mL of 50° liquor or 350mL of 5° beer); or those who do not agree to abstain from smoking or drinking during the trial; or those whose alcohol breath test results are positive;
16. (Screening period consultation) Those who have taken any prescription drugs, over-the-counter drugs, any vitamin products or Chinese herbal medicines (JAK inhibitors, immunosuppressants, etc.) within 14 days before screening;
17. (Screening period consultation/check-in consultation) Concomitant use of strong inducers of liver metabolic enzymes (such as: omeprazole, barbiturates, carbamazepine, aminolutamide) within 4 weeks (28 days) before screening (e.g., griseofulvin, methamphetamine, phenytoin, glutamidate, rifampicin, sulfinpyrazone, roxithromycin, etc.), or others judged by the investigator to be likely to affect the pharmacokinetics of the test drug in vivo Medication history learner. Those who have taken any drugs known to cause QT/QTcF interval prolongation or drugs with a risk of causing torsade de pointes (TdP) within 4 weeks (28 days) before screening; or those with long half-life;
18. (Screening period consultation/check-in consultation) Within 48 hours before administration, consumption of any food or beverage containing caffeine (such as coffee, strong tea, cola, chocolate, etc.), or containing grapefruit juice, etc. may affect metabolism. Foods that may affect enzymes, or those who consume alcoholic foods or drinks;
19. (Screening period consultation/check-in consultation + online screening) Those who participated in other clinical trials and used investigational drugs, vaccines or devices within 3 months before the first dose;
20. (Screening period consultation/check-in consultation) Pregnant or lactating women or women of childbearing age who have had unprotected sexual intercourse within 14 days before screening;
21. (Screening period interview/check-in interview) During the trial, the subject or his partner is unwilling to use non-drug contraceptive methods (such as complete abstinence, condoms, IUDs, sterilization, etc.) for contraception or after administration of study drugs The subject and/or his or her partner have pregnancy plans within 3 months;
22. The subject may not be able to complete the study due to other reasons or the researcher may think there are other factors that make him or her unsuitable to participate in the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Flunotinib treatment group; Subjects in this group will take flunotinib	Drug: flunotinib; Day one will be used for drug administration, and Day two~Day seven will be used for experimental data collection.; Other Names: 25mg flunotinib; 50mg flunotinib; 100mg flunotinib; 150mg flunotinib; 200mg flunotinib
Placebo Comparator: placebo group; Subjects in this group will take flunotinib placebo	Drug: flunotinib placebo; Day one will be used for drug administration, and Day two~Day seven will be used for experimental data collection.; Other Names: 25mg flunotinib placebo; 50mg flunotinib placebo; 100mg flunotinib placebo; 150mg flunotinib placebo; 200mg flunotinib placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prilinostat Mesylate Pharmacokinetics (PK)：Cmax	Estimation of maximum observed plasma concentration	Day one to day seven
Prilinostat Mesylate Pharmacokinetics (PK)：Tmax	Estimation of time to reach Cmax	Day one to day seven
The statistical parameters of fecal pharmacokinetics are the cumulative excretion of prototype drugs and major metabolites in feces (Ae0-144h) and excretion rate (Ae%);	security indicators	Day one to day seven
Prilinostat Mesylate Pharmacokinetics (PK)：AUC0-∞	Estimation of AUC from time zero extrapolated to infinity	Day one to day seven
Prilinostat Mesylate Pharmacokinetics (PK)：MRT	Estimation of mean residence time	Day one to day seven
Prilinostat Mesylate Pharmacokinetics (PK)：Vd	Estimation of apparent volume of distribution	Day one to day seven
Prilinostat Mesylate Pharmacokinetics (PK)：t1/2	Estimation of terminal elimination half-life	Day one to day seven
Prilinostat Mesylate Pharmacokinetics (PK)：CLz/F	Estimation of clearance when dosed orally	Day one to day seven
Prilinostat Mesylate Pharmacokinetics (PK)：Vz/F	Estimation of apparent volume of distribution when dosed orally	Day one to day seven
Prilinostat Mesylate Pharmacokinetics (PK)：Ke	Estimation of the elimination rate constant of a drug in the body	Day one to day seven

Collaborators and Investigators

• Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
• Investigators: Principal Investigator: Xiaolan Yong, Xiaolan, Chengdu Xinhua Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 29, 2024
• Primary Completion (Estimated): August 29, 2024
• Study Completion (Estimated): December 30, 2024

Study Registration Dates

• First Submitted: March 6, 2024
• First Submitted That Met QC Criteria: April 23, 2024
• First Posted (Actual): April 29, 2024

Study Record Updates

• Last Update Posted (Actual): April 29, 2024
• Last Update Submitted That Met QC Criteria: April 23, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: H-FNTN-PI-Ia

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No